Display options
Cite
Cardenas-de la Garza JA, Arvizu-Rivera RI, Galarza-Delgado DA. Should patients starting biologics be screened for COVID-19?. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218437.
Cardenas-de la Garza, J. A., Arvizu-Rivera, R. I., & Galarza-Delgado, D. A. (2020). Should patients starting biologics be screened for COVID-19?. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218437
Cardenas-de la Garza, Jesus Alberto, et al. "Should patients starting biologics be screened for COVID-19?." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218437
Cardenas-de la Garza JA, Arvizu-Rivera RI, Galarza-Delgado DA. Should patients starting biologics be screened for COVID-19?. Ann Rheum Dis. 2020 Jul 06; doi: 10.1136/annrheumdis-2020-218437. Epub 2020 Jul 06. PMID: 32632031.
Copy Download .nbib Format: NLM
Share it on

Ann Rheum Dis. 2020 Jul 06; doi: 10.1136/annrheumdis-2020-218437. Epub 2020 Jul 06.

Should patients starting biologics be screened for COVID-19?.

Annals of the rheumatic diseases

Jesus Alberto Cardenas-de la Garza, Rosa I Arvizu-Rivera, Dionicio Angel Galarza-Delgado

Affiliations

  1. Rheumatology, University Hospital "Dr José E González", Universidad Autónoma de Nuevo León, Monterrey, México.
  2. Internal Medicine, University Hospital "Dr José E González", Universidad Autónoma de Nuevo León, Monterrey, México.
  3. Rheumatology, University Hospital "Dr José E González", Universidad Autónoma de Nuevo León, Monterrey, México [email protected].

PMID: 32632031 DOI: 10.1136/annrheumdis-2020-218437

[No abstract available.]

Keywords: antirheumatic agents; autoimmune diseases; biological therapy; immune system diseases; tumor necrosis factor inhibitors

Conflict of interest statement

Competing interests: None declared.

Publication Types